Loading...
ZY logo

Zymergen Inc.NasdaqGS:ZY Voorraadrapport

Marktkapitalisatie US$253.6m
Prijs aandeel
n/a
Mijn reële waarde
n.v.t.
1Y-76.7%
7D3.4%
1D
Portefeuillewaarde
​
Bekijk

Zymergen Inc.

NasdaqGS:ZY Voorraadrapport

Marktkapitalisatie: US$253.6m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Zymergen (ZY) Aandelenoverzicht

Zymergen Inc. design, develop, and commercialize microbes, molecules, and materials. Meer informatie

Risicoanalyse

Heeft minder dan 1 jaar cash runway

De omzet is het afgelopen jaar met 22.1% gedaald

Volatiele aandelenkoers in de afgelopen 3 maanden vergeleken met de US markt

Aanzienlijke insider-verkoop in de afgelopen 3 maanden


ZY Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Zymergen Inc. Concurrenten

Prijsgeschiedenis en prestaties

Overzicht van hoogtepunten, dieptepunten en veranderingen in de aandelenkoersen voor Zymergen
Historische aandelenkoersen
Huidige aandelenkoersUS$2.43
52 Week HoogtepuntUS$11.87
52 Week LaagUS$1.10
Bèta0
1 maand verandering-6.90%
3 maanden verandering21.50%
1 Jaar Verandering-76.75%
3 jaar veranderingn/a
5 jaar veranderingn/a
Verandering sinds IPO-93.55%

Recent nieuws en updates

Seeking Alpha • Aug 25

Zymergen chief scientific officer to depart as company lays off more employees

Zach Serber, chief scientific officer of Zymergen (NASDAQ:ZY) and a co-founder, is leaving the company on Sept. 22. Zymergen (ZY) also said it is laying off another 80 employees. This follows the termination of 80 employees in late July. The company's shares are down 63% year to date. Seeking Alpha's Quant Rating views Zymergen (ZY) as a hold.
Seeking Alpha • Jul 26

Zymergen: Ginkgo Bioworks Acquisition

An acquisition was probably the only viable option for Zymergen, but shareholders are likely to be disappointed by the price, given the company’s ambitions at the IPO. The deal makes sense for Ginkgo as it reduces competition and expands its capabilities at a minimal cost. An all-stock transaction gives Zymergen shareholders exposure to a company with much brighter prospects, but there is a significant downside risk if Ginkgo stumbles in the future. Ginkgo Bioworks (DNA) has entered into an agreement to acquire Zymergen (ZY). While Zymergen shareholders are unlikely to be thrilled by the price, the company's financial position gave them little option. Ginkgo continues to solidify their position as the leading synbio platform, but is richly valued based on current operating metrics. The all-stock deal gives Zymergen shareholders exposure to a company with better prospects, but also introduces valuation risk. Zymergen At the time of Zymergen's IPO, the company appeared to be reaching an inflection point, with multiple products nearing commercialization. Zymergen's narrative and valuation fell apart soon after though, when the company announced these products were not viable and that the CEO would be stepping down. Since then, Zymergen has been in a race to restructure costs and create revenue streams, in the hope of staving off bankruptcy. Given the company's cost structure, balance sheet and the state of equity markets, an acquisition was probably the best hope for shareholders. Figure 1: Zymergen Target Opportunities (source: Zymergen) Automation & Tech Platform Zymergen had been in the process of offering modular automation systems to the market, to commercialize their lab expertise. In particular, Octant had purchased 11 of Zymergen's Reconfigurable Automation Carts (RACs) to help scale their drug discovery platform. These RACs are designed to improve the throughput, efficiency, and reliability of lab operations and are controlled by Zymergen's cloud software. Zymergen previously stated that they had approximately 30 prospects, with a typical 10-RAC system costing between 1-2.5 million USD and requiring approximately 400,000 USD in annual software and support costs. Figure 2: Zymergen RAC (source: Zymergen) Advanced Materials Zymergen have been developing materials, which they have bracketed under agriculture, water repellency, advanced polymers and enzymes. Zymergen has a fairly mature nitrogen fixation program that uses engineered microbes to replace nitrogen fertilizers. In their water repellency program, Zymergen have been exploring coated straws and recently demonstrated the successful conversion of their coated paper into an end product manufactured on a potential customer's production line. Within advanced polymers, Zymergen has announced a supply agreement with 3D4Makers to provide Polyimide for use in 3D printing. Polyimide is a high-strength polymer that is flame retardant, has excellent insulating properties and excellent thermal stability. The polymer will be offered to 3D4Maker's customers for applications like aerospace, automotive, and transportation. Zymergen has also developed mRNA enzymes (VCE and 2'-O-MT) for use in vaccines. Drug Discovery Zymergen is leveraging their metagenomic database to uncover natural molecules that inhibit targets of interest, with an initial focus on oncology. There are millions of novel bioactives from uncultured bacteria and fungi and Zymergen are computationally predicting the activity of these bioactives against human targets. Figure 3: Therapeutic Classes and Potential Targets (source: Zymergen) Ginkgo Acquisition Ginkgo is acquiring Zymergen in an all-stock transaction that values Zymergen at approximately a 300 million USD market capitalization. The stated aim of the acquisition is to accelerate the development of Ginkgo's platform. Ginkgo plan to integrate Zymergen's automation, software, data science tools and biological assets. Zymergen's core technical team will be retained, which will help Ginkgo to fulfill their hiring plans. Strategic alternatives will be considered for Zymergen's Advanced Materials and Drug Discovery businesses. It is possible that these will be spun out and become Ginkgo customers, in a similar manner to companies like Joyn Bio and Motif Food Works. Ginkgo has been active in M&A in recent years, with acquisitions either building on the capabilities of their Foundries, or providing the necessary vertical expertise to attract customers and successfully bring products to market. Figure 4: Ginkgo Acquisitions (source: Ginkgo Bioworks) Ginkgo is doing the right thing by conducting countercyclical M&A, but it is unclear how much value Zymergen will add. Ginkgo's appeal should be that they have singular capabilities, and acquiring competing synbio companies for their technology undermines this. Jason Kelly stated that approximately 70% of the deal's value lies in Zymergen's physical assets (foundry / automation). There could be significant issues integrating these assets into Ginkgo's workflows, although Zymergen's successful rollout of automation solutions at Octant has given Ginkgo confidence that this can be managed. Figure 5: Ginkgo's Plan for Zymergen's Assets (source: Ginkgo Bioworks) In its current state, Zymergen would significantly weaken Ginkgo's financial position, and hence it is likely that there will be a large reduction in headcount. Zymergen had approximately 500 employees at the end of 2021 in comparison to Ginkgo's 640 employees, but is not currently generating any meaningful revenue.
Seeking Alpha • Jul 14

Zymergen expands agreement with Octant on developing breakthrough medicines

Biotech company Zymergen (NASDAQ:ZY) expanded an agreement with therapeutics company Octant in relation to developing breakthrough medicines. Octant has more than doubled its initial investment through the purchase of six additional Reconfigurable Automation Carts, or RAC, units. ZY shares were trading +2.15% post-market. Source: Press Release

Recent updates

Seeking Alpha • Aug 25

Zymergen chief scientific officer to depart as company lays off more employees

Zach Serber, chief scientific officer of Zymergen (NASDAQ:ZY) and a co-founder, is leaving the company on Sept. 22. Zymergen (ZY) also said it is laying off another 80 employees. This follows the termination of 80 employees in late July. The company's shares are down 63% year to date. Seeking Alpha's Quant Rating views Zymergen (ZY) as a hold.
Seeking Alpha • Jul 26

Zymergen: Ginkgo Bioworks Acquisition

An acquisition was probably the only viable option for Zymergen, but shareholders are likely to be disappointed by the price, given the company’s ambitions at the IPO. The deal makes sense for Ginkgo as it reduces competition and expands its capabilities at a minimal cost. An all-stock transaction gives Zymergen shareholders exposure to a company with much brighter prospects, but there is a significant downside risk if Ginkgo stumbles in the future. Ginkgo Bioworks (DNA) has entered into an agreement to acquire Zymergen (ZY). While Zymergen shareholders are unlikely to be thrilled by the price, the company's financial position gave them little option. Ginkgo continues to solidify their position as the leading synbio platform, but is richly valued based on current operating metrics. The all-stock deal gives Zymergen shareholders exposure to a company with better prospects, but also introduces valuation risk. Zymergen At the time of Zymergen's IPO, the company appeared to be reaching an inflection point, with multiple products nearing commercialization. Zymergen's narrative and valuation fell apart soon after though, when the company announced these products were not viable and that the CEO would be stepping down. Since then, Zymergen has been in a race to restructure costs and create revenue streams, in the hope of staving off bankruptcy. Given the company's cost structure, balance sheet and the state of equity markets, an acquisition was probably the best hope for shareholders. Figure 1: Zymergen Target Opportunities (source: Zymergen) Automation & Tech Platform Zymergen had been in the process of offering modular automation systems to the market, to commercialize their lab expertise. In particular, Octant had purchased 11 of Zymergen's Reconfigurable Automation Carts (RACs) to help scale their drug discovery platform. These RACs are designed to improve the throughput, efficiency, and reliability of lab operations and are controlled by Zymergen's cloud software. Zymergen previously stated that they had approximately 30 prospects, with a typical 10-RAC system costing between 1-2.5 million USD and requiring approximately 400,000 USD in annual software and support costs. Figure 2: Zymergen RAC (source: Zymergen) Advanced Materials Zymergen have been developing materials, which they have bracketed under agriculture, water repellency, advanced polymers and enzymes. Zymergen has a fairly mature nitrogen fixation program that uses engineered microbes to replace nitrogen fertilizers. In their water repellency program, Zymergen have been exploring coated straws and recently demonstrated the successful conversion of their coated paper into an end product manufactured on a potential customer's production line. Within advanced polymers, Zymergen has announced a supply agreement with 3D4Makers to provide Polyimide for use in 3D printing. Polyimide is a high-strength polymer that is flame retardant, has excellent insulating properties and excellent thermal stability. The polymer will be offered to 3D4Maker's customers for applications like aerospace, automotive, and transportation. Zymergen has also developed mRNA enzymes (VCE and 2'-O-MT) for use in vaccines. Drug Discovery Zymergen is leveraging their metagenomic database to uncover natural molecules that inhibit targets of interest, with an initial focus on oncology. There are millions of novel bioactives from uncultured bacteria and fungi and Zymergen are computationally predicting the activity of these bioactives against human targets. Figure 3: Therapeutic Classes and Potential Targets (source: Zymergen) Ginkgo Acquisition Ginkgo is acquiring Zymergen in an all-stock transaction that values Zymergen at approximately a 300 million USD market capitalization. The stated aim of the acquisition is to accelerate the development of Ginkgo's platform. Ginkgo plan to integrate Zymergen's automation, software, data science tools and biological assets. Zymergen's core technical team will be retained, which will help Ginkgo to fulfill their hiring plans. Strategic alternatives will be considered for Zymergen's Advanced Materials and Drug Discovery businesses. It is possible that these will be spun out and become Ginkgo customers, in a similar manner to companies like Joyn Bio and Motif Food Works. Ginkgo has been active in M&A in recent years, with acquisitions either building on the capabilities of their Foundries, or providing the necessary vertical expertise to attract customers and successfully bring products to market. Figure 4: Ginkgo Acquisitions (source: Ginkgo Bioworks) Ginkgo is doing the right thing by conducting countercyclical M&A, but it is unclear how much value Zymergen will add. Ginkgo's appeal should be that they have singular capabilities, and acquiring competing synbio companies for their technology undermines this. Jason Kelly stated that approximately 70% of the deal's value lies in Zymergen's physical assets (foundry / automation). There could be significant issues integrating these assets into Ginkgo's workflows, although Zymergen's successful rollout of automation solutions at Octant has given Ginkgo confidence that this can be managed. Figure 5: Ginkgo's Plan for Zymergen's Assets (source: Ginkgo Bioworks) In its current state, Zymergen would significantly weaken Ginkgo's financial position, and hence it is likely that there will be a large reduction in headcount. Zymergen had approximately 500 employees at the end of 2021 in comparison to Ginkgo's 640 employees, but is not currently generating any meaningful revenue.
Seeking Alpha • Jul 14

Zymergen expands agreement with Octant on developing breakthrough medicines

Biotech company Zymergen (NASDAQ:ZY) expanded an agreement with therapeutics company Octant in relation to developing breakthrough medicines. Octant has more than doubled its initial investment through the purchase of six additional Reconfigurable Automation Carts, or RAC, units. ZY shares were trading +2.15% post-market. Source: Press Release
Seeking Alpha • Jun 03

Zymergen Seeks Turnaround But Runway Is Running Low

Zymergen went public in April 2021, raising around $500 million in an IPO. The firm designs advanced materials technologies to improve manufacturing processes. ZY has been decimated by the market after no revenue in 2021/2022 and the sudden departure of its CEO. While the firm has been restructured, it only has one year of cash runway, which isn't much for a zero revenue and high operating loss company.
Seeking Alpha • May 23

Zymergen: A Humbled Company With A Business On The Ropes

The stock for Zymergen Inc. has been in freefall since an initial recovery attempt following last year's disaster. The company will run out of cash in 2023 and prospects for viability remain murky. Of the many research and development projects underway, reconfigurable automation carts offer the most likely foundation for earning an 11th-hour infusion of cash. The coming full-time CEO will have to hit the ground running with a major sense of urgency to pull Zymergen off the ropes.
Analyseartikel • Mar 27

Some Zymergen Inc. (NASDAQ:ZY) Analysts Just Made A Major Cut To Next Year's Estimates

Today is shaping up negative for Zymergen Inc. ( NASDAQ:ZY ) shareholders, with the analysts delivering a substantial...
Analyseartikel • Mar 25

Zymergen Inc. (NASDAQ:ZY) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Zymergen Inc. ( NASDAQ:ZY ) missed earnings with its latest full-year results, disappointing overly-optimistic...
Seeking Alpha • Dec 09

Zymergen: Total Chaos

Rather than achieving a growth inflection point, Zymergen recently abandoned their most mature products and rationalized their product portfolio. The CEO has been replaced and the co-founder and operations chief has stepped down, along with a hiring freeze and a large headcount reduction, all of which point towards problems. Zymergen no longer has a clear path to profitability, which raises questions about the company as an ongoing concern.
Seeking Alpha • Aug 05

Zymergen: How To Buy A Disaster

Shares in Biofacturing company Zymergen (ZY) collapsed in epic fashion after a catastrophic setback in its commercialization plans. The stock is now significantly de-risked and worthy of speculation. I am considering a bet on the company's cash position, new management, and promising technology.
Analyseartikel • Aug 05

Analysts Just Made A Major Revision To Their Zymergen Inc. (NASDAQ:ZY) Revenue Forecasts

Market forces rained on the parade of Zymergen Inc. ( NASDAQ:ZY ) shareholders today, when the analysts downgraded...

Rendement voor aandeelhouders

ZYUS ChemicalsUS Markt
7D3.4%0.1%1.1%
1Y-76.7%8.9%28.7%

Rendement versus industrie: ZY presteerde slechter dan de US Chemicals -sector, die het afgelopen jaar een rendement van 8.9 % opleverde.

Rendement versus markt: ZY presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 28.7 % opleverde.

Prijsvolatiliteit

Is ZY's price volatile compared to industry and market?
ZY volatility
ZY Average Weekly Movement13.3%
Chemicals Industry Average Movement7.5%
Market Average Movement7.2%
10% most volatile stocks in US Market16.5%
10% least volatile stocks in US Market3.1%

Stabiele aandelenkoers: De aandelenkoers van ZY is de afgelopen 3 maanden volatiel geweest in vergelijking met de US markt.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 13% ) van ZY is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen US.

Over het bedrijf

OpgerichtWerknemersCEOWebsite
2013505n/awww.zymergen.com

Zymergen Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Zymergen zich tot de beurswaarde?
ZY fundamentele statistieken
MarktkapitalisatieUS$253.58m
Inkomsten(TTM)-US$364.92m
Inkomsten(TTM)US$14.58m
17.4x
P/S-verhouding
-0.7x
Koers/Winstverhouding

Is ZY overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
ZY resultatenrekening (TTM)
InkomstenUS$14.58m
Kosten van inkomstenUS$178.03m
Brutowinst-US$163.45m
Overige uitgavenUS$201.47m
Inkomsten-US$364.92m

Laatst gerapporteerde inkomsten

Jun 30, 2022

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)-3.50
Brutomarge-1,121.15%
Nettowinstmarge-2,503.04%
Schuld/Eigen Vermogen Verhouding0%

Hoe presteerde ZY op de lange termijn?

Bekijk historische prestaties en vergelijking

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2022/10/23 20:41
Aandelenkoers aan het einde van de dag2022/10/18 00:00
Inkomsten2022/06/30
Jaarlijkse inkomsten2021/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Zymergen Inc. wordt gevolgd door 5 analisten. van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
Derik de BruinBofA Global Research
Matthew SykesGoldman Sachs
Sriharsha PappuHSBC